… between COPD and asthma, we excluded patients who also had … COPD is not appropriately
controlled with monotherapy.7 Recently, several novel inhaled long-acting bronchodilators …

… Overall forest plot meta-analysis of the impact of long-acting muscarinic antagonist/long-acting
β2-agonist combinations on trough FEV 1 and subgroup analysis performed on lower and …

… As previously mentioned, the two drugs investigated in this study are typically used in COPD
patients and as such have more research data in that patient population. Glycopyrronium …

… include long-acting inhaled bronchodilators (long-acting beta 2 -… COPD mainly for prediction
of exacerbations and the need for ICS. As with asthma, FeNO levels in patients with COPD …

… chronic obstructive pulmonary disease (COPD) patients, combination treatment with long-acting
muscarinic antagonist (LAMA) and long-acting … asthma could be enrolled, if the asthma …

… cardiovascular control in COPD patients. Further investigations are needed to explore
mechanisms by which long-acting bronchodilators may increase cardiovascular events in COPD. …

… CLINICAL IMPLICATIONS: Nebulized once-daily revefenacin, a novel LAMA in development
for the treatment of COPD, may be an important future treatment option, subject to the …

… bronchodilators. Citation1 LABA monotherapy is contraindicated for patients with asthma, …
the comparative efficacy of long-acting bronchodilators for COPD found that indacaterol was …

… ) bronchodilators as first-line therapy to address disease symptoms and to prevent exacerbations
in patients with chronic obstructive pulmonary disease (COPD). … Revefenacin, a novel, …

… In addition, it would be useful to perform a study in a large population of patients with
asthma–chronic obstructive pulmonary disease overlap, in which we would expect good …